<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Mon, 06 Apr 2026 11:01:05 -0400--><rss version="2.0">
    <channel>
        <title>Intensity Therapeutics, Inc. (INTS) Press Releases</title>
        <link>https://ir.intensitytherapeutics.com/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/intensitytherapeutics/files/theme/images/logo-sm.png</url>
                <title>Intensity Therapeutics, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/123/intensity-therapeutics-reports-2025-year-end-financial</link>
                <pubDate>Fri, 27 Mar 26 16:12:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/123/intensity-therapeutics-reports-2025-year-end-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/122/intensity-therapeutics-strengthens-ip-portfolio-with</link>
                <pubDate>Tue, 24 Mar 26 08:00:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/122/intensity-therapeutics-strengthens-ip-portfolio-with</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/121/intensity-therapeutics-inc-provides-update-on-the-phase-2</link>
                <pubDate>Thu, 12 Mar 26 07:30:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/121/intensity-therapeutics-inc-provides-update-on-the-phase-2</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/120/intensity-therapeutics-regains-compliance-with-nasdaqs</link>
                <pubDate>Fri, 06 Mar 26 07:47:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/120/intensity-therapeutics-regains-compliance-with-nasdaqs</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Announces Reverse Stock Split]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/119/intensity-therapeutics-announces-reverse-stock-split</link>
                <pubDate>Fri, 13 Feb 26 08:58:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/119/intensity-therapeutics-announces-reverse-stock-split</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/118/intensity-therapeutics-highlights-2025-milestones-and</link>
                <pubDate>Tue, 13 Jan 26 07:47:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/118/intensity-therapeutics-highlights-2025-milestones-and</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/117/intensity-therapeutics-inc-to-present-two-posters-at-the</link>
                <pubDate>Thu, 11 Dec 25 07:47:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/117/intensity-therapeutics-inc-to-present-two-posters-at-the</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/116/intensity-therapeutics-granted-180-day-extension-to-regain</link>
                <pubDate>Fri, 05 Dec 25 07:30:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/116/intensity-therapeutics-granted-180-day-extension-to-regain</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/115/intensity-therapeutics-announces-two-presentations-at-the</link>
                <pubDate>Thu, 04 Dec 25 07:47:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/115/intensity-therapeutics-announces-two-presentations-at-the</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/114/intensity-therapeutics-reports-third-quarter-2025-financial</link>
                <pubDate>Thu, 06 Nov 25 16:02:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/114/intensity-therapeutics-reports-third-quarter-2025-financial</guid>
                                                                            </item>
            </channel>
</rss>